Beiersdorf update
This article was originally published in The Rose Sheet
Executive Summary
Sales in the first two months of the year increased 9% at constant exchange rates, German company announces at annual press conference in Hamburg April 2. Based upon early sales figures, Beiersdorf predicts sales for the year will rise 7% to about $5.34 bil. (€1=$1.09). Profit after taxes is expected to represent 6% of sales, Beiersdorf adds. Growth will be driven by continuous investment in key brands including Nivea, Juvena, La Prairie, 8x4 and Atrix, accelerated development of international markets and new products, firm states...
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.